Park Soo-Kyung, Choi Chang Hwan, Chun Jaeyoung, Lee Heeyoung, Kim Eun Sun, Park Jae Jun, Park Chan Hyuk, Lee Bo-In, Jung Yunho, Park Dong-Il, Kim Do Young, Park Hana, Jeen Yoon Tae
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Intest Res. 2020 Jan;18(1):18-33. doi: 10.5217/ir.2019.09155. Epub 2020 Jan 30.
The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.
在过去十年中，免疫调节剂和生物制剂的使用日益增加，彻底改变了炎症性肠病（IBD）的治疗方式。对于接受此类免疫抑制治疗的IBD患者而言，机会性感染是一个重要的安全问题。特别是，病毒性肝炎取决于病毒与宿主免疫力之间的相互作用，并且如果免疫抑制疗法损害了免疫力，病毒再激活的风险就会增加。与美国和西欧相比，包括韩国在内的部分亚洲地区，甲型肝炎病毒和乙型肝炎病毒的流行程度仍处于中等水平。因此，韩国肠道疾病研究协会IBD研究小组的成员制定了一份关于IBD患者病毒性肝炎预防和管理的指南。
